drugset / Trial / NCT01154790

Phase I Study on Multiple Oral Dosing of CG100649

NCT01154790

Phase 1 Completed 120 enrolled CrystalGenomics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of 3 escalating loading and maintenance dose regimens of CG100649 administered orally for 7 total days in healthy volunteers.

Timeline

Start
2010-06
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule
Subject Polmacoxib Other / unclassified Oral

Indications

No indication recorded.